ARS Pharmaceuticals annual r&d spending
2020
2021
2022
2023
2024
2025
ARS Pharmaceuticals R&D Spending Growth & History (SPRY)
ARS Pharmaceuticals's r&d spending was $13.2M for fiscal 2025.
View full ARS Pharmaceuticals company overviewARS Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13.2M | −$6.4M | −32.68% |
| 2024 | 2024-12-31 | $19.6M | −$686,000 | −3.38% |
| 2023 | 2023-12-31 | $20.3M | $1.9M | +10.29% |
| 2022 | 2022-12-31 | $18.4M | −$1.9M | −9.36% |
| 2021 | 2021-12-31 | $20.3M | −$4.3M | −17.51% |
| 2020 | 2020-12-31 | $24.6M | — | — |
ARS Pharmaceuticals quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.7M | $663,000 | +16.43% |
| Q1 2026 | 2026-03-31 | $4.3M | $1.4M | +46.88% |
| Q4 2025 | 2025-12-31 | $3.4M | $416,000 | +13.74% |
| Q3 2025 | 2025-09-30 | $2.8M | −$1.7M | −37.80% |
| Q2 2025 | 2025-06-30 | $4.0M | −$2.9M | −41.49% |
| Q1 2025 | 2025-03-31 | $3.0M | −$2.3M | −43.60% |
| Q4 2024 | 2024-12-31 | $3.0M | −$377,000 | −11.08% |
| Q3 2024 | 2024-09-30 | $4.4M | $1.4M | +47.34% |
| Q2 2024 | 2024-06-30 | $6.9M | −$412,000 | −5.64% |
| Q1 2024 | 2024-03-31 | $5.2M | −$1.3M | −20.12% |
| Q4 2023 | 2023-12-31 | $3.4M | −$1.3M | −27.73% |
| Q3 2023 | 2023-09-30 | $3.0M | −$891,000 | −22.89% |
| Q2 2023 | 2023-06-30 | $7.3M | $3.0M | +68.00% |
| Q1 2023 | 2023-03-31 | $6.6M | $1.1M | +20.82% |
| Q4 2022 | 2022-12-31 | $4.7M | — | — |
| Q3 2022 | 2022-09-30 | $3.9M | −$11.7M | −75.11% |
| Q2 2022 | 2022-06-30 | $4.3M | −$13.4M | −75.49% |
| Q1 2022 | 2022-03-31 | $5.4M | −$6.8M | −55.69% |
| Q3 2021 | 2021-09-30 | $15.6M | $9.4M | +152.27% |
| Q2 2021 | 2021-06-30 | $17.7M | $12.6M | +246.25% |
| Q1 2021 | 2021-03-31 | $12.2M | $7.8M | +177.28% |
| Q4 2020 | 2020-12-31 | $8.8M | — | — |
| Q3 2020 | 2020-09-30 | $6.2M | — | — |
| Q2 2020 | 2020-06-30 | $5.1M | — | — |
| Q1 2020 | 2020-03-31 | $4.4M | — | — |
ARS Pharmaceuticals r&d spending trends
Over the last five fiscal years, ARS Pharmaceuticals's r&d spending decreased from $24.6M to $13.2M, a change of −$11.4M. The latest reported quarter, Q2 2026, shows $4.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ARS Pharmaceuticals source filings ↗